School of Medicine
Showing 1-20 of 61 Results
Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine
Current Research and Scholarly Interests Recent clinical studies, by us and others, have demonstrated that T cell based immunotherapy can eradicate cancers resistant to all other available therapies. Our program creates, develops and optimizes genetically engineered T cells to treat cancer. We link the bench with the bedside, developing novel therapies for early phase testing in clinical trials, while simultaneously conducting intensive studies on clinical samples obtained from patients treated on immunotherapy trials.
David Magnus, Ph.D.
Thomas A. Raffin Professor in Medicine and Biomedical Ethics and Professor (Teaching) of Medicine (Primary Care and Population Health)
Current Research and Scholarly Interests Genetic testing, gene therapy, genetically engineered organisms, and the history of eugenics. Stem cell research and cloning, and egg procurement. Examining ethical issues in reproductive technologies. Organ transplantation including donation after cardiac death, ethics of listing decisions. End of life issues in both adults and children.
Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center
Bio Clinical Focus: Cardiovascular Medicine
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Vice Chair of Clinical Research in the Department of Medicine and Member of the Stanford IRB
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Vice Chair of Clinical Research, Department of Medicine
Clinical Professor, Medicine - Primary Care and Population Health
Current Research and Scholarly Interests Stanford Primary Care delivers innovative, high-quality, personalized and holistic care for patients and families throughout their lives. We are leading the shift from a health care system focused on medical care for individual patients toward an integrated health system focused on health and wellness of a population. Stanford Primary Care partners with multiple stakeholders across Stanford Health Care and Stanford University to achieve the quadruple aim.
Academic Staff - Hourly - CSL, Medicine - Cardiovascular Medicine
Bio Dr. Anurag Mairal is an Adjunct Professor of Medicine and the Director, Global Outreach Programs at Stanford Byers Center for Biodesign, Stanford University. He is also an Adjunct Professor at Stanford's Graduate School of Business and a Faculty Fellow and Lead for Technology Innovation and Impact at Center for Innovation in Global Health. In these roles, he leads initiatives focused on applying the biodesign process to resource-constrained settings globally. Further, he facilitates opportunities for students, faculty and fellows at Stanford to work on global healthcare needs. He is part of the founding faculty team for MED 232, Global Health: Scaling Health Technology Innovations in Low Resource Settings and BIOE 371, Global Biodesign: Medical Technology in an International Context, graduate-level courses offered to engineering, business, and medical students at Stanford University. Earlier, he served as Associate Director for the Stanford-India Biodesign and Singapore-Stanford Biodesign programs. He serves as the Founding Chair of BME IDEA APAC, a community of medtech innovation programs in Asia Pacific, partnering closely with the industry and academia in the region. He is also an Honorary Professor at University of Cape Town, South Africa. Concurrently, he is a co-founder and Executive Vice President of Orbees Medical, a SF Bay Area-based strategy consulting firm serving global healthcare industry, with a focus on medtech, pharmaceutical, and digital health industry.
Dr. Mairal has an extensive background in medical technology development and commercialization, collaborating with partners in the U.S., India, China, and other emerging markets to advance product development, manufacturing, and distribution. Recently, he took a sabbatical for two years to take a senior leadership role at PATH, a major global health nonprofit based in Seattle. In this role, he oversaw research and development, commercialization, and implementation of technologies in PATH’s medical devices, diagnostics, and digital health divisions. Previously, he held several positions at Johnson & Johnson, including Business Development Director and Product Director for structural heart, cardiology, and peripheral vascular products at Cordis. Before joining J&J, he was a Group Leader and a Process Development Manager at Membrane Technology and Research (MTR). At MTR, he was responsible for business development, strategic alliances, and product development in the bioseparations area. An active mentor to entrepreneurs and industry professionals, he serves as the chair of PATH’s Bay Area Leadership Council, board member at EPPIC Global Network and IIT Bombay Heritage Foundation and advisory board member at D-Rev and Sewa International.
Dr. Mairal earned a PhD in chemical engineering from the University of Colorado at Boulder and an MBA from the Haas School of Business at the University of California at Berkeley. He also holds an MS in chemical engineering from the Indian Institution of Technology in Mumbai and a BS in chemical engineering from National Institute of Technology, Raipur. Dr. Mairal was a post-doctoral fellow at the University of Twente, Netherlands and at University of Michigan, Ann Arbor. At BerkeleyHaas, he was a founding co-Chairman of the South Asia Business Conference and Chair of the Biotech Panel for the Asia Business Conference. His work has been published in more than 30 publications, and he has seven issued patents.
Ravindra Majeti MD, PhD
Professor of Medicine (Hematology)
Current Research and Scholarly Interests The Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for human hematopoietic cells.
Academic Staff - Hourly - CSL, Medicine - Cardiovascular Medicine
Current Research and Scholarly Interests Dr. Josh Makower serves on the faculty of the Stanford University Medical School as an Adjunct Professor of Medicine and is Co-Founder of Stanford’s Biodesign Innovation Program (now called the Byers Center for Biodesign). Josh helped create the fundamental structure of the Center’s core curriculum and is the chief architect of what is now called “The Biodesign Process.” Over the past 18 years since Josh and Dr. Paul Yock founded the Stanford Biodesign Innovation Program, this curriculum and the associated textbook has been used at Stanford and across the world to train thousands of students, faculty and industry leaders on the biodesign process towards the advancement of medical innovation for the improvement of patient care. Josh has practiced these same techniques directly as the Founder & Executive Chairman of ExploraMed, a medical device incubator, creating 8 companies since 1995. Transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard & TransVascular, acquired by Medtronic. Other ExploraMed/NEA ventures include Moximed, Nuelle and Willow. Josh is currently also working with NEA where he is a General Partner on their healthcare team leading the medtech/healthtech practice. Josh serves on the board of Setpoint Medical, DOTS Technologies, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow and Coravin. Josh holds over 300 patents and patent applications. He received an MBA from Columbia University, an MD from the NYU School of Medicine, a bachelor’s degree in Mechanical Engineering from MIT and is a Member of the College of Fellows of The American Institute for Medical and Biological Engineering and was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018.
Jose R. Maldonado, MD, FAPM
Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology-Adult) and, by courtesy, of Emergency Medicine and of Medicine at the Stanford University Medical Center and, by courtesy, of Law
Current Research and Scholarly Interests Pathophysiology and Management of Delirium, Acute Brain Failure and Cognitive Impairment, Neuropsychiatric Sequelae of Traumatic Brain Injury, Factitious Disorder & Munchausen's Syndrome, Cultural Diversity in Medical Care, Psychiatric Complications of Bone Marrow Transplantation, Conversion Disorder, Depression in the Medically Ill, Neuropsychiatric Sequelae of Chronic Fatigue Syndrome.
Professor (Clinical) of Medicine (Endocrinology, Gerontology and Metabolism), Emeritus
Current Research and Scholarly Interests I have been retired since 2008 and no longer conduct research
Clinical Assistant Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine
Bio Dr. Marmor is a board certified pulmonary specialist. She specializes in the treatment of individuals with chronic airway disease, bronchiectasis, and chronic lung infections.
David J. Maron
Clinical Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly Interests Dr. Maron is the Co-Chair and Principal Investigator of the ISCHEMIA trial, and Co-Chair of the ISCHEMIA-CKD trial. These large, international, NIH-funded studies will determine whether an initial invasive strategy of cardiac catheterization and revascularization plus optimal medical therapy will reduce cardiovascular events in patients with and without chronic kidney disease and at least moderate ischemia compared to an initial conservative strategy of optimal medical therapy alone.